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Using quantitative RT-PCR, we compared mRNA levels for TRAIL [tumor necrosis factor (TNF)–related apoptosis-inducing
ligand] and its receptors in various immune cell subsets derived from the peripheral blood of untreated normal subjects (NS)
and patients with distinct subtypes of multiple sclerosis (MS): active relapsing-remitting MS (RRA), quiescent relapsing-remitting
MS (RRQ), secondary-progressive MS (SPMS) or primary-progressive MS (PPMS). Consistent with a role for TRAIL in the
mechanismofactionofinterferon-β (IFN-β),TRAILmRNAlevelswereincreasedinmonocytesfrompatientsclinicallyresponsive
to IFN-β (RRQ) but not those unresponsive to this therapeutic (RRA). TRAIL-R3 (decoy receptor) expression was elevated
in T cells from untreated RRMS patients while IFN-β therapy reversed this increase suggesting that IFN-β may promote the
apoptotic elimination of autoreactive T cells by increasing the amount of TRAIL available to activate TRAIL death receptors.
Serum concentrations of soluble TRAIL were increased to a similar extent by IFN-β therapy in RRQ, RRA and SPMS patients that
had not generated neutralizing antibodies against this cytokine. Although our ﬁndings suggest altered TRAIL signaling may play a
role in MS pathogenesis and IFN-β therapy, they do not support use of TRAIL as a surrogate marker for clinical responsiveness to
this therapeutic.
1.Introduction
Multiple sclerosis (MS) is a chronic neurodegenerative
autoimmune disorder characterized by CNS inﬂammation,
demyelination,andaxonalinjuryresultinginclinicalrelapses
anddisability[1–3].MSisconsideredtobeaTcell-mediated
disease [4, 5] in which failed apoptotic deletion of autoreac-
tive T cells has been implicated as a pathogenic mechanism
[6, 7]. Apoptosis plays an important role in immune system
homeostasis by eliminating autoreactive immune cells that
mightotherwisepromoteautoimmunity[8].Tumornecrosis
factor- (TNF-)related apoptosis-inducing ligand (TRAIL)
plays a key regulatory function in this regard by activating
death receptors present on various cellular components of
the immune system such as T cells, B cells, and monocytes
[9]. As a result, a number of immune cell subtypes have
been implicated in autoimmunity subsequent to the loss
of TRAIL function [9]. Although CD4+ T cells speciﬁc for
myelin antigens are thought to initiate and exacerbate MS
through secretion of proinﬂammatory cytokines, peripheral
blood monocytes may also contribute to this disease by
migrating to the CNS and releasing inﬂammatory mediators
that trigger nerve and tissue damage [1, 2, 10–12]. In the
case of B lymphocytes, three lines of evidence suggest these
immune cells are involved in MS pathogenesis: increased
myelin-speciﬁcantibodies,presenceofBcellsreactiveagainst
myelin, and the ability of the anti-CD20 antibody Rituximab
to deplete B cells and reduce relapses and disease burden as
assessed by MRI [11–14].
TRAIL, also known as Apo2 ligand (Apo2L), is a
member of the TNF superfamily that shares 24% amino acid
homology with the death receptor CD95 (Fas/ApoL) ligand
[15]. TRAIL and CD95L can promote the apoptotic death of
a number of cancer cells [15]. Despite TRAIL mRNA being2 Autoimmune Diseases
present in a wide variety of tissue types, most normal cells
are resistant to TRAIL cytotoxicity [15]. CNS inﬂammation
in MS is associated with elevated expression of TRAIL,
both within the CNS and autoreactive immune cells [16–
18]. TRAIL inhibits activated T cell proliferation through
intricate interactions with various receptors for this cytokine
[19]. The initial TRAIL receptor identiﬁed, death receptor
4 (DR4 or TRAIL-R1), transmits proapoptotic signals via a
cytoplasmic death domain. DR5 or TRAIL-R2 also contains
a DR4-like death domain that conveys apoptotic signaling
[15]. TRAIL-R3 and TRAIL-R4 lack the cytoplasmic tails
found in TRAIL-R1 and TRAIL-R2 necessary to trigger
apoptosis and therefore act as decoy receptors [15]. These
decoy receptors prevent TRAIL-induced apoptosis and rep-
resent an important mechanism for regulating the apoptotic
sensitivity of immune cells. The selective expression of
decoy receptors in normal tissues has led to the proposal
that TRAIL may be useful for preferentially inducing the
apoptosis of cancer cells [15].
TRAIL has been implicated in both MS pathogenesis
and the mechanism of action of interferon-beta (IFN-β), a
disease modifying therapy that has been used to treat MS
for over twenty years [19–21]. Recombinant IFN-β therapy
istypicallyemployedforthetreatmentofrelapsing-remitting
MS(RRMS).Althoughtheprecisemechanism(s)responsible
for the beneﬁcial eﬀects of IFN-β in the treatment of MS
remain unclear, the abilities of this cytokine to inhibit T-
cell activation and proliferation as well as facilitate the apop-
totic elimination of autoreactive T cells are thought to be
therapeutically relevant [22]. TRAIL/Apo2L-deﬁcient mice
subjected to myelin oligodendrocyte glycoprotein-induced
experimental autoimmune encephalomyelitis (EAE) display
increased T-cell proliferative responses, more inﬂammatory
lesions in the spinal cord and brain, and elevated clinical
scores relative to wild-type littermates, while peripheral
administration of recombinant TRAIL reduces EAE severity
[23]. Moreover, IFN-β increases circulating levels of soluble
TRAIL (sTRAIL) and the expression of membrane-bound
TRAIL (mbTRAIL) in immune cells derived from the
peripheral blood of MS patients [21, 24]. TRAIL may
therefore contribute to the mechanism of action of IFN-β
by promoting the apoptosis of autoreactive immune cells
in MS patients. IFN-β is not curative but reduces disease
progressionasevidencedbydecreasedfrequencyandseverity
of relapses. However, some patients are unresponsive to IFN-
β therapy and continue to experience relapses and disease
progression while treated with this therapeutic [25]. The
reasons why some patients respond to IFN-β therapy while
others do not beneﬁt remain unclear. The present study
therefore sought to determine whether the expression of
TRAIL and/or its receptors in peripheral blood immune cells
from treated and nontreated MS patients discriminated IFN-
β responders from IFN-β nonresponders.
2.MaterialsandMethods
2.1. Patient Selection and Blood Sampling. One hundred
ninety-nine participants were recruited for this study includ-
ing participants with RRMS (n = 100), SPMS (n = 38),
and PPMS (n = 30) as well as thirty-one healthy control
subjects from the community, matched for age and gender.
Study inclusion criteria included deﬁnite MS (RRMS, SPMS,
PPMS) according to consensus deﬁnitions, 18 years of age
or older, and if being treated with IFN-β, patients were on a
stabledosefor6monthshavinghadadosewithin8–16hours
prior to blood draw. Several disease modifying therapies
(DMTs) have been approved for relapse-onset MS (RRMS
and SPMS with superimposed relapses). First line agents,
include three diﬀerent preparations of interferon-β (IFN-
β)( I F N - β1a or Avonex, IFN-β1b or Betaseron, and IFN-β1
or Rebif) and glatiramer-acetate (Copaxone). Natilizumab
(Tysabri) and mitoxantrone (Novantrone) are considered
second line therapies and used for treatment of more aggres-
sive forms of relapse-onset MS [26–28]. For the purpose
of this study, RRMS patients were assigned into “active”
and “quiescent” groups based on their clinical condition
at the time of blood collection. Relapsing-remitting active
(RRA) disease was deﬁned in patients that had experienced
one or more clinical relapse(s) or had Gd+ enhancing
lesion(s) on MRI in the previous year (n = 41). Relapsing-
remitting quiescent (RRQ) disease was deﬁned in patients
that had neither relapses within the previous year nor EDSS
progression over the same time period (n = 59). These
clinical deﬁnitions of active and quiescent MS are supported
by diﬀerences in the expression of members of the Inhibitor
of Apoptosis family in peripheral blood mononuclear cells
and T cells derived from such patients [29].
Both MS patients and control subjects had an absence
of other major medical illness including cancer and autoim-
mune disease. Study exclusion criteria for all subjects
included treatment with immunosuppressive therapy or
treatment with intravenous methylprednisolone within 3
months of study participation. All participants provided
written informed consent prior to study participation
according to the Declaration of Helsinki. All participants
meetinginclusion/exclusioncriteriaprovidedabloodsample
totaling 38mL into four 8mL BD Vacutainer sodium citrate
Ficoll gradient tubes, one serum tube, and/or one Paxgene
(Qiagen) whole blood RNA tube.
2.2. Cell Puriﬁcation, RNA Extraction, and TRAIL Quantiﬁ-
cation. Whole blood RNA was isolated using the PAXgene
whole blood RNA kit as per manufacturer’s instructions
and as previously described [29]. For the isolation of highly
puriﬁed T cells, B cells or monocytes, 400μLo fR o s e t t e S e p T ,
RosetteSepB, or RosetteSep monocytes (Stem Cell Technolo-
gies, B.C.), respectively, was added to three separate Ficoll-
gradient tubes (Becton, Dickinson and Company; BD Vacu-
tainer CPT Cell Preparation Tube with Sodium Citrate). All
tubes (T cells, B cells, monocytes) were centrifuged at 1650–
1800×g for 25 minutes in a swinging bucket centrifuge. The
T cells, B cells, or monocytes were transferred to separate
15ml conical centrifugation tubes, treated with ammonium
chloride(StemCellTechnologies,Vancouver,B.C.)toremove
any remaining red blood cells, and centrifuged to pellet the
cells. RNA was extracted from cell pellets using the RNeasy
kit (Qiagen). FACS analyses were performed to conﬁrm the
purity (95–98%) of immune cell populations. Total RNAAutoimmune Diseases 3
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Figure 1:RelativequantiﬁcationofTRAILmRNAexpressioninRNAextractedfromwholeblood,Tcells,Bcells,andmonocytesemploying
qRT-PCR. (a) In whole blood, TRAIL gene expression was no diﬀerent between the various groups. (b) In T cells, TRAIL gene expression
was also no diﬀerent among NS and the various patient groups. (c) In B cells, TRAIL gene expression was the same in the various groups
examined. (d) In monocytes, TRAIL gene expression was increased in RRQ IFN and SPMS IFN patients relative to NS. TRAIL mRNA was
also elevated in RRQ IFN relative to RRQ NO IFN. ∗P<. 05,∗∗P<. 01 and ∗∗∗P<. 001, Dunn’s post hoc test.
yields were measured by ultraviolet (UV) absorbance, and
RNA samples were diluted in RNAse free water to give a ﬁnal
concentration of 10ng/μL.
2.3. Quantitative RT-PCR. Quantitative RT-PCR (qRT-
PCR) was performed to conﬁrm changes in TRAIL, TRAIL-
R1 (DR4), TRAIL-R2 (DR5), TRAIL-R3 (TRAIL decoy
receptor), and TRAIL-R4 (TRAIL decoy receptor) mRNA
levels in diﬀerent subtypes of untreated and treated MS
patients relative to normal control subjects. Data were ﬁrst
stratiﬁed according to MS disease subtype activity and
IFN-β treatment. If statistical comparisons between these
groups were not signiﬁcant, data were pooled and analyzed
according to overall disease classiﬁcation (RRMS, SPMS,
PPMS). Total RNA (50ng) was reverse transcribed to yield
ﬁrst-strand cDNA and ampliﬁed using the Taqman one-step
EZ RT-PCR Core reagents kit (Applied Biosystems, Foster
City, CA, USA). The expression of beta (β) actin was used as
anendogenouscontrolreference(AppliedBiosystems,Foster
City, CA, USA). Primers for TRAIL and its receptors were
made according to previously published sequences [30–32]
(see Table 1). Although the intent was to compare TRAIL
proﬁles amongst all samples collected, in some cases this
was precluded due to decreased RNA yields. Results were
expressed in Fold change relative to a “calibrator.” The
calibrator sample was the RNA sample from a normal age-
matched female subject [33].
2.4. ELISA. Blood was collected in a 3ml serum separator
tube, allowed to clot at RT for 1 hour and centrifuged
at 1000×g for 20 minutes. Serum was transferred to two
1 . 5m le p p e n d o r ft u b e sa n ds t o r e da t−80◦C until analyses.
Enzyme linked-immunosorbent assay (ELISA) measured
soluble TRAIL as per manufacturer’s instructions (R&D
systems, Minneapolis, MN USA). Serum (50μl in duplicate)
from normal healthy control subjects (NS, n = 34), RRMS
and SPMS patients treated with IFN-β (RRMS IFN, n =
41; SPMS IFN, n = 16), RRMS and SPMS patients not4 Autoimmune Diseases
Tc e l l s
10
9
8
7
6
5
4
3
2
1
0
F
o
l
d
i
n
c
r
e
a
s
e
T
R
A
I
L
-
R
1
SPMS
(n = 30)
PPMS
(n = 20)
RRQ
NO IFN
(n = 18)
RRQ
IFN
(n = 19)
RRA
NO IFN
(n = 23)
RRA
IFN
(n = 9)
NS
(n = 18)
(a)
SPMS
(n = 30)
PPMS RRQ
NO IFN
RRQ
IFN
(n = 19)
RRA
NO IFN
(n = 23)
RRA
IFN
(n = 9)
NS
Tc e l l s
10
1
9
8
7
6
5
4
3
2
0
F
o
l
d
i
n
c
r
e
a
s
e
T
R
A
I
L
-
R
2
(n = 22)
(n = 19)
(n = 20)
(b)
Tc e l l s
F
o
l
d
i
n
c
r
e
a
s
e
T
R
A
I
L
-
R
3
SPMS
(n = 13)
NS
(n = 16) NO IFN
(n = 9)
RRMS
IFN
(n = 29)
RRMS
20
15
10
5
0
PPMS
(n = 5)
∗ ∗∗∗
(c)
Tc e l l s
10
9
8
7
6
5
4
3
2
1
0
F
o
l
d
i
n
c
r
e
a
s
e
T
R
A
I
L
-
R
4
NS
(n = 10)
SPMS
(n = 9)
PPMS
(n = 5) (n = 45)
RRMS
(d)
Figure 2: Relative quantiﬁcation of TRAIL death (TRAIL-R1, TRAIL-R2) and decoy receptor (TRAIL-R3, TRAIL-R4) mRNAs in T cells.
(a) In T cells, there were no diﬀerences in gene expression of TRAIL-R1 and (b) TRAIL-R2. (c) TRAIL-R3 gene expression was increased
in RRMS NO IFN patients relative to the NS group while administration of IFN-β reversed this increase in RRMS patients (RRMS IFN).
∗P<. 05 and ∗∗P<. 01, Dunn’s posthoc test.
Table 1: Human Taqman Probe and Primer Sequences. Taqman probe andp r i m e rs e q u e n c e sf o rT R A I La n di t sr e c e p t o r s( R )h a v eb e e n
previously published.
Human gene Human primer and probe sequences
TRAIL
Forward 5 -GCTCTGGGCCGCAAAAT-3 
Reverse 5 -TGCAAGTTGCTCAGGAATGAA-3 
Probe 5 -(FAM)ACTCCTGGGAATCATCAAGGAGTGGGC(TAMRA)-3 
TRAIL-R1
Forward 5 -TGTACGCCCTGGAGTGACAT-3 
Reverse 5 -CACCAACAGCAACGGAACAA-3 
Probe 5 -(FAM)TGTCCACAAAGAATCAGGCAATGGACATAAT(TAMRA)-3 
TRAIL-R2
Forward 5 -CACTCACTGGAATGACCTCCTTT-3 
Reverse 5 -GTGCAGGGACTTAGCTCCACTT-3 
Probe 5 -(FAM)TCACACCTGGTGCAGCGCAAGCAG(TAMRA)-3 
TRAIL-R3
Forward 5 -TCTCCACGCGCACGAAC-3 
Reverse 5 -CCCCTTGCATCTCTGGTCAA-3 
Probe 5 -(FAM)CAGCCAACGATTTCTGATAGATTTTTGGGAG(TAMRA)-3 
TRAIL-R4
Forward 5 -TTGGCGCTTTCGATCCAC-3 
Reverse 5 -CGGTCGGGACGCTTTGT-3 
Probe 5 -(FAM)CTCCTCCCTTCTCATGGGACTTTGGG(TAMRA)-3 Autoimmune Diseases 5
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Figure 3: Relative quantiﬁcation of TRAIL death (TRAIL-R1, TRAIL-R2) and decoy receptor (TRAIL-R3, TRAIL-R4) mRNAs in B cells.
(a) TRAIL-R1, (b) TRAIL-R3 and (d) TRAIL-R4 mRNA levels were not altered by IFN-β treatment or diﬀerent between the various groups
(NS group and MS subtypes). Insuﬃcient amounts of B cell RNA were isolated to permit analysis of TRAIL-R4 levels for PPMS patients. (c)
TRAIL-R3 gene expression was increased in SPMS patients irrespective of IFN-β treatment condition (SPMS NO IFN and SPMS IFN groups
not diﬀerent and therefore pooled) relative to the RRMS group. ∗P<. 05, Dunn’s post-hoc test.
treated with IFN-β (RRMS NO IFN, n = 32; SPMS NO
IFN, n = 12), and PPMS (n = 23) were analyzed for
soluble TRAIL (sTRAIL) using an ELISA with a monoclonal
antibody speciﬁc for human TRAIL according to manufac-
turer’s instructions (R&D Systems, Minneapolis, MN). All
measurements were performed in duplicate.
2.5. Statistical Analyses. A nonparametric test (Kruskal-
Wallis test) was used to compare potential diﬀerences in
expression of mRNAs encoding TRAIL, TRAIL-R1, TRAIL-
R2, TRAIL-R3, and TRAIL-R4 in whole blood, T cells, B cells
and monocytes derived from the peripheral whole blood of
thevariousgroups(NSandpatientswithsubtypesofMSthat
were either treated or not treated with IFN-β). If signiﬁcant
atanalphaofP ≤ .01,Dunn’sposttestwasusedtodetermine
whether diﬀerences existed between individual groups. The
Mann Whitney U test was used to compare soluble TRAIL
protein levels in blood serum from NAB(−)a n dN A B ( + )
MSpatients. Statistical tests wereperformedusing GraphPad
Prismversion4forWindows,GraphPadSoftware,SanDiego
California USA, http://www.graphpad.com/.
3. Results
3.1. IFN-β Increases TRAIL MRNA in Monocytes from RRQ
andSPMSPatients. UsingRNAderivedfromwholeblood,T
cells or B cells, no diﬀerences in TRAIL gene expression were
observed between the diﬀerent subtypes of IFN-β-treated
and untreated MS patient populations (Figures 1(a)–1(c)).
In peripheral monocytes, however, a signiﬁcant increase in
TRAILgeneexpressionwasobservedinbothRRQandSPMS
patients treated with IFN-β relative to normal subjects (NS)
(Figure 1(d)). Relative to untreated RRQ patients (RRQ NO
IFN), a signiﬁcant increase in TRAIL gene expression was
also observed in IFN-β-treated RRQ patients (RRQ IFN).
3.2. TRAIL-R3 mRNA Is Elevated in T Cells from RRMS
a n dT h i sI n c r e a s eI sR e v e r s e db yI F N - β Treatment. In T6 Autoimmune Diseases
cells, no diﬀerences in either TRAIL-R1 or TRAIL-R2 were
observedbetweenthevariousgroups(Figures2(a)and2(b)).
There was, however, a signiﬁcant increase in TRAIL-R3
mRNA in T cells from untreated RRMS patients relative to
NS (Figure 2(c)). Interestingly, IFN-β-treatment in RRMS
patients reversed this increase in TRAIL-R3 mRNA such that
expression levels of this gene were signiﬁcantly decreased
in T cells from IFN-β-treated RRMS patients relative to
untreated RRMS patients. No diﬀerences in TRAIL-R3
mRNA were observed in whole blood or monocytes (data
not shown). Quantitative RT-PCR analysis for TRAIL-R4
revealed no diﬀerences across disease subtypes in either T
cells (Figure 2(d)), monocytes, or whole blood (data not
shown).
3.3. TRAIL-R3 mRNA Is Increased in B Cells from SPMS
Relative to RRMS Patients. In B cells, no diﬀerences in
TRAIL-R1, TRAIL-R2, or TRAIL-R4 were observed (Figures
3(a), 3(b),a n d3(d)). A signiﬁcant increase in TRAIL-R3
mRNA expression was observed in SPMS patients relative to
RRMS patients (Figure 3(c)). No eﬀects of IFN-β treatment
were noted in this analysis (data not shown).
3.4. IFN-β Increases Soluble TRAIL in Serum Regardless of
MS Subtype or Disease Activity. The range of soluble TRAIL
(sTRAIL) in serum was between 21.6 and 157.2pg/mL
(Figure 4(a)) for the NS group. In the three patient popula-
tions treated with IFN-β, (RRQ IFN, RRA IFN, and SPMS
IFN), serum concentrations of sTRAIL were signiﬁcantly
increased relative to NS (Figure 4(a)). While not indicated
on Figure 4(a), statistical signiﬁcance (P<. 001) was also
observed between the RRQ NO IFN and RRQ IFN groups
as well as the RRA NO IFN and RRA IFN groups. These
ﬁndings conﬁrm our earlier qRT-PCR results demonstrating
that IFN-β-treated patients had elevated TRAIL mRNA in
peripheral monocytes suggesting that a major source of
sTRAIL is from this particular cell type. When patients were
grouped according to the presence of neutralizing antibodies
against IFN-β, a signiﬁcant decrease in sTRAIL was observed
in the NAB(+) relative to NAB(−) patients (Figure 4(b)).
4. Discussion
In this retrospective study, we ﬁrst compared levels of TRAIL
mRNA in whole blood, T cells, B cells, and monocytes
isolatedfromtheperipheralbloodofhealthynormalsubjects
(NS) and MS patients treated with various preparations
of IFN-β. Only in monocytes were signiﬁcant diﬀerences
in TRAIL gene expression detected between NS and MS
patients that received IFN-β. Elevated TRAIL gene expres-
sion associated with IFN-β therapy was correlated with
clinical responsiveness to this therapeutic in RRMS patients
as suggested by higher levels of monocytic TRAIL mRNA
in RRQ, but not RRA, patients relative to the NS group.
H o w e v e r ,T R A I Lm R N Al e v e l sw e r en o td i ﬀerent between
RRQ and RRA patients that received IFN-β, indicating
that clinical responsiveness to this therapeutic cannot be
distinguished purely on this basis. This ﬁnding was both
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Figure 4: Absolute quantiﬁcation of soluble TRAIL protein in
p e r i p h e r a lb l o o ds e r u m .( a )L e v e l so fs o l u b l eT R A I Lp r o t e i nw e r e
increased in serum from IFN-β treated-patients irrespective of
subgroup (RRMS, SPMS) or disease activity (RRQ, RRA) relative
to NS and untreated MS patients. ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<
.001, Dunn’s post-hoc test. (b) Ten patients (RRQ IFN n = 4; RRA
IFN n = 3; SPMS n = 3) that were NAB(+) showed attenuated
sTRAIL levels relative to IFN-β NAB(−) MS patients. ∗∗∗P<. 001,
Mann Whitney U test.
supported and extended by our measurements of soluble
TRAIL levels in peripheral blood serum. In this case, IFN-
β treatment produced a comparable elevation of soluble
TRAIL levels in both RRQ and RRA patients relative to
the NS group. Furthermore, in patients that were NAB+,
the ability of IFN-β to elevate soluble TRAIL levels was
lost. Thus, while TRAIL induction appears to depend upon
the availability of biologically active IFN-β, blood levels of
this death receptor ligand did not distinguish RRA from
RRA patients. These results are in agreement with ﬁndings
from a recent prospective study that reported levels of
soluble TRAIL in blood plasma failed to predict clinical
responsiveness of RRMS patients to IFN-β [34].
TRAIL-R3 encodes a decoy receptor that suppresses the
apoptotic activity of TRAIL [35]. In the present study,
we found that expression of TRAIL-R3, but not that forAutoimmune Diseases 7
the death-inducing receptors TRAIL-1 and TRAIL-2 or the
second TRAIL decoy receptor known as TRAIL-R4, is to
be elevated in T cells from RRMS patients. TRAIL-R3
expression has also been found to be selectively elevated in
T cell lines derived from MS patients compared to those
from healthy donors [36]. Moreover, we observed in RRMS
patients treated with IFN-β that expression of TRAIL-R3was
reduced to levels similar to that detected in healthy controls.
WespeculatethatbyreducingTRAIL-3levelsonTcells,IFN-
β may enhance the proapoptotic and antiproliferative eﬀects
of TRAIL on these immune cells. In keeping with this line
of reasoning, we also observed TRAIL-R3 expression in B
cells from SPMS patients to be enhanced relative to RRMS
patients that may reﬂect immune mechanisms which could
conceivably contribute to disease progression. To the best of
ourknowledge,thisistheﬁrstdemonstrationthatTRAIL-R3
may be involved in both the mechanism of action of IFN-β
as well as MS disease progression.
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